The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to life sciences company LabCorp’s Pixel by LabCorp COVID-19 Test Home Collection Kit.

The test is the first of its kind to be available over the counter without needing a prescription. It is indicated for use in people aged 18 years and above.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

With the latest development, LabCorp can potentially sell the kit through its retail channels.

Using the kit, customers can self-collect the sample at their own home, containing the virus transmission. After collecting the sample, users can send it for processing at LabCorp.

LabCorp Diagnostics chief medical officer and president Dr Brian Caveney said: “With the first over-the-counter at-home collection kit ever authorised by the FDA for Covid-19, we are empowering people to learn about their health and make confident decisions.

“With this authorisation, we can help more people get tested, reduce the spread of the virus, and improve the health of our communities.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

After purchasing the Pixel by LabCorp COVID-19 collection kit, users are asked to register it at the Pixel by LabCorp website and follow the instructions provided.

The company will send the kit to collect the nasal swab sample, which needs to be shipped back to its lab. The test for SARS-CoV-2 virus will be conducted in the lab.

Users will be able to access the results through the website.

According to LabCorp, the average time to deliver results after receiving the sample is one to two days.

If the user tests positive for Covid-19, a healthcare professional will provide guidance to help with the treatment.

LabCorp’s Covid-19 PCR test has been authorised only for the detection of nucleic acid from SARS-CoV-2 and cannot be used for testing any viruses or pathogens.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact